M. Battegay

Discipline

Economies et finances (7) Psychologie (2) Anthropologie biologique (2) Sociologie (1) Démographie (1)

Type de document

Articles (74) Recensions (2)

Co-auteur

Date

Source

Mot-clé

cohorte (56) Treatment (51) Swiss (49) Human beings (49) thérapie (44) Therapeutics (44) Patients (44) Patients (44) virus (34) adulte (34) adulte (34) Methods (33) Methods (33) Older people (31) Immunodeficiency (30) infection (28) Infection (28) Use (28) Confidence (26) temps (durée) (24) Time (24) analyse (23) Ci (Chinese poetry) (23) Analysis (23) Sex (22) risque (21) art (21) Art (21) Art (21) Risk (21)

Documents écrit par M. Battegay (74) | parle de M. Battegay (0)

Impact of Obesity on the Drug-Drug Interaction Between Dolutegravir and Rifampicin or Any Other Strong Inducers
M. Berton et al.
Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland.
P. Thoueille et al. (29 juil. 2022)
Physiologically Based Pharmacokinetic Modelling to Investigate the Impact of the Cytokine Storm on CYP3A Drug Pharmacokinetics in COVID-19 Patients
F. Stader et al.
Evolution of COVID-19 mortality over time: results from the Swiss hospital surveillance system (CH-SUR).
M. Roelens et al. (22 nov. 2021)
Physiologically-Based Pharmacokinetic Modeling to Support the Clinical Management of Drug-Drug Interactions With Bictegravir
F. Stader et al.
Assessing the drivers of syphilis among men who have sex with men in Switzerland reveals a key impact of screening frequency: A modelling study.
S. Balakrishna et al.
Genetic variation near CXCL12 is associated with susceptibility to HIV-related non-Hodgkin lymphoma.
C.W. Thorball et al. (1 août 2021)
Systematic screening of viral and human genetic variation identifies antiretroviral resistance and immune escape link.
H. Nguyen et al. (1 juin 2021)
Physiologically-Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV.
F. Stader et al.
Association of Incomplete Adherence to Antiretroviral Therapy With Cardiovascular Events and Mortality in Virologically Suppressed Persons With HIV: The Swiss HIV Cohort Study.
J.R. Castillo-Mancilla et al.
Sex Differences in Lopinavir Concentrations and Occurrence of Marked QTc Prolongation Episodes in Patients with COVID-19
C. Marzolini et al.
Global Genomic Analysis of SARS-CoV-2 RNA Dependent RNA Polymerase Evolution and Antiviral Drug Resistance
A. Mari et al. (2021)
Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART.
C. Wan et al. (2 nov. 2020)
Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations
C. Marzolini et al. (2020)
Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect
F. Stader et al. (2020)
Repeated Syphilis Episodes in HIV-Infected Men Who Have Sex With Men: A Multicenter Prospective Cohort Study on Risk Factors and the Potential Role of Syphilis Immunity.
J.A. Roth et al.
Polypharmacy, Drug-Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV.
P. Courlet et al.
Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART.
N. Bachmann et al. (19 juil. 2019)
Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications
F. Stader et al.
Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study.
K. Kusejko et al.
Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity.
C. Kadelka et al. (4 juin 2018)
Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity.
F. Bertels et al. (1 janv. 2018)
Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis.
T. Turk et al. (12 sept. 2017)
Adverse events of raltegravir and dolutegravir.
L. Elzi et al. (24 août 2017)
Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study.
D. Sculier et al. (6 juil. 2017)

next